Clinical Trials Directory

Trials / Completed

CompletedNCT00828438

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Eisai Inc. · Industry
Sex
All
Age
18 Years – 79 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the PK properties of lorcaserin in subjects with end stage renal disease (ESRD) who require dialysis and will be studied under dialysis and non-dialysis conditions.

Conditions

Interventions

TypeNameDescription
DRUGLorcaserin 10mg

Timeline

Start date
2008-10-01
Primary completion
2009-02-01
Completion
2009-02-01
First posted
2009-01-26
Last updated
2019-09-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00828438. Inclusion in this directory is not an endorsement.